Novo Nordisk investors are being asked to hold three distinct storylines apart this month: a regulatory green light for its weekly insulin, a set of exploratory weight-loss readouts, and fresh head-to-head competition data from Eli Lilly. Blurring them together risks drawing conclusions the underlying evidence does not support.
Start with the clearest signal. On 23 October the US Food and Drug Administration approved Awiqli as a once-weekly basal insulin for children aged ten and older with type-2 diabetes, aimed at improving blood-sugar control. That is a regulatory decision — a different category of event entirely from the conference abstracts and post-hoc analyses that make up the rest of Novo’s near-term news flow.
A conference calendar, not a verdict
Novo has contributions lined up for “The Liver Meeting,” running 5–9 November in Denver. According to the company, these include analyses of semaglutide drawn from real-world clinical practice as well as post-hoc evaluations of the ESSENCE study. Real-world data and retrospective analyses can sharpen the picture of how a drug performs, but the mere announcement of presentations does not establish that Novo has strengthened its competitive position.
The CagriSema programme illustrates why that distinction matters. On 20 October Novo reported post-hoc analyses from REDEFINE 1 in women: average weight loss of 25.0% after 68 weeks, against 3.0% on placebo. The company explicitly labelled the findings exploratory, and CagriSema remains an investigational compound. Those results are neither an approval decision nor a secured commercial success.
Lilly’s comparison cuts one way only
Competitive pressure intensified with a direct comparison study from Eli Lilly reported the previous day. Retatrutide, still in development, delivered 20%–21% weight loss over 80 weeks in a Phase 3 head-to-head trial, according to company figures, versus 9% for Ozempic at a 2 mg dose. Media reports of the same study describe stronger A1C reductions and more than double the average weight loss for retatrutide in adults with type-2 diabetes.
The reference point is narrow and worth stating plainly: the trial tested Ozempic, not CagriSema. No ranking against Novo’s other candidates can be inferred from it, and the study offers no direct retatrutide-versus-CagriSema comparison. Setting the 25.0% CagriSema figure beside Lilly’s retatrutide numbers would not prove superiority either way — one is a post-hoc analysis of a specific participant subgroup, the other a prospective head-to-head trial.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Two questions, two answers
What investors actually have in front of them is a pair of non-interchangeable statements. Lilly reports an advantage over the Ozempic regimen it studied. Novo points to weight-loss data for a different candidate. Both are relevant; they should not be fused into a single study result, and the direct comparison and the retrospective analysis deserve separate treatment in any assessment of the shares.
A stronger result for another company’s drug, or in another patient group, does not automatically answer the same clinical question Novo is asking.
The 4 November anchor
The next financial checkpoint arrives on 4 November, when Novo Nordisk is scheduled to publish results for the first nine months of 2026. That date shifts attention from the clinical arena to the business itself, and the coming numbers will provide an additional reference point for valuation.
Until then, the discipline is to keep three ledgers apart: regulatory progress confirmed by the FDA, treatment options still under investigation, and the commercial trajectory that the November print will lay bare. The latest study data raise the competitive temperature, but they are no substitute for an assessment of the underlying business.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from October 29 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 29.
Novo Nordisk: Buy or sell? Read more here...
